---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-25-007654"
form_type: "8-K"
ticker: "PROF"
cik: "0001628808"
company_name: "Profound Medical Corp."
filed_at: "2025-11-28T23:59:59+00:00"
generated_at: "2026-05-16T16:09:43.001985+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Profound Medical launches AI-powered TULSA-AI Volume Reduction module for BPH; TAM could triple to ~600K patients

## Summary
- Launched TULSA-AI Volume Reduction module for BPH at RSNA; reduces procedure times and enables same-day stacking.
- CEO Arun Menawat says module could triple total addressable market to ~600,000 patients annually.
- CAPTAIN randomized trial data shows TULSA superior to robotic prostatectomy in blood loss, length of stay, and pain.
- TULSA Procedure is the only incision-free therapy for both prostate cancer and BPH with customizable precision.
- Profound to present new TULSA-PRO data at RSNA and SUO meetings through Dec 5, 2025.

## SEC filing metadata
- accession: 0001171843-25-007654
- form_type: 8-K
- ticker: PROF
- cik: 0001628808
- company_name: Profound Medical Corp.
- filed_at: 2025-11-28T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1628808/000117184325007654/0001171843-25-007654-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1628808/000117184325007654/f8k_112825.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-25-007654
- JSON: https://secwatch.observer/filing/0001171843-25-007654.json
- Plain text: https://secwatch.observer/filing/0001171843-25-007654.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.